文献速递抗栓抗凝管理特殊人群用药

阿替普酶与阿加曲班治疗COVID-19相关大面积肺栓塞一例

Thrombolysis and use of argatroban for the treatment of massive pulmonary embolism following anticoagulation failure in a patient with COVID-19.
PubMed 文献 · Am J Health Syst Pharm · 2020-01-01

本病例报告描述一名42岁男性COVID-19患者,在疑似低分子量肝素治疗深静脉血栓失败后发生大面积肺栓塞并心脏骤停,给予两剂50mg静脉阿替普酶后恢复自主循环,后续使用低剂量阿加曲班抗凝且无并发症。这是首例在既往抗凝失败后使用阿加曲班治疗COVID-19相关心脏骤停性大面积肺栓塞的病例报告。结论认为阿加曲班可作为低分子量肝素治疗失败的COVID-19患者的替代抗凝策略,但需权衡风险与获益并讨论剂量。

要点

  • COVID-19患者低分子量肝素治疗失败后,阿加曲班可作为替代抗凝策略。
  • 两剂50mg静脉阿替普酶使心脏骤停的大面积肺栓塞患者恢复自主循环。
  • 使用阿加曲班前需进行风险获益讨论并关注剂量选择。

核心结论

  • 阿加曲班可作为低分子量肝素治疗失败的COVID-19患者的替代抗凝策略。
  • 需就治疗适宜性和剂量进行风险与获益讨论。
  • 需要更多数据了解COVID-19患者独特的高凝状态及阿加曲班和比伐卢定的作用。

研究设计与样本

  • 病例报告:一名42岁男性COVID-19患者。
  • 患者发生大面积肺栓塞导致心脏骤停,疑似低分子量肝素治疗深静脉血栓失败。

主要发现

  • 给予两剂50mg静脉阿替普酶后恢复自主循环。
  • 后续使用低剂量阿加曲班抗凝,无并发症。
  • 这是首例在既往抗凝失败后使用阿加曲班治疗COVID-19相关心脏骤停性大面积肺栓塞的病例报告。

关键数值与推荐

  • 阿替普酶:两剂50mg静脉给药。
  • 阿加曲班:低剂量作为后续抗凝治疗。

临床怎么用

  • 对于低分子量肝素治疗失败的COVID-19患者,可考虑阿加曲班作为替代抗凝策略。
  • 使用阿加曲班时需进行风险获益讨论并关注剂量选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Successful use of alteplase and argatroban to treat a patient with coronavirus disease 2019 (COVID-19)-associated massive pulmonary embolism with cardiac arrest is reported. SUMMARY: This case report describes a 42-year-old male with COVID-19 who developed a massive pulmonary embolism resulting in cardiac arrest after suspected failure of low-molecular-weight heparin therapy for a deep venous thrombosis. Administration of two 50-mg doses of intravenous alteplase resulted in return of spontaneous circulation, and low-dose argatroban was used as follow-up anticoagulation therapy without complications. This is the first case report of use of argatroban in a patient with COVID-19 with cardiac arrest-associated massive pulmonary embolism after failure of previous anticoagulation efforts. CONCLUSION: Argatroban may be used as an alternate anticoagulation strategy in COVID-19 patients who fail low-molecular weight therapy. A risk versus benefit discussion should be had regarding appropriateness of therapy as well as dosing. More data is needed to understand the unique hypercoagulable condition in COVID-19 patients as well as research that further highlights the role of argatroban and bivalirudin therapy in this patient population.

来源:Am J Health Syst Pharm,查看原文。版权归原作者所有。

引用

  1. Sagardia LM, Daniels LM. Thrombolysis and use of argatroban for the treatment of massive pulmonary embolism following anticoagulation failure in a patient with COVID-19. Am J Health Syst Pharm. 2020. PMID: 32780853. doi:10.1093/ajhp/zxaa287

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。